QUuniQure QURE · NASDAQ
$25.30 +1.32% (+$0.33)
- Market cap
- $1.75B
- Enterprise value
- $1.40B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 94.0x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -23.1%
- Gross margin
- 22.8%
- Net margin
- -1,350.7%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.94
- Free float
- 82.9%
About the company
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew C. Kapusta
Employees
221
Headquarters
Amsterdam
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Analysts expect revenue to grow by 44% this fiscal year.
- What to watch: Revenue fell by 47% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $413.0M against $62.8M.
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number